Table 2.
Comparison of Thyrotropin and Antithyroglobulin Antibodies Cohorts with the Overall NTCTCS Population
| Parameter | Overall differentiated thyroid cancer cohort since 1996 | Preoperative TSH cohort | Perioperative TgAb cohort |
|---|---|---|---|
| Number of patients (n) |
3308 |
617 |
1701 |
| Percent female (%) |
72.2 |
76.3a |
72.7 |
| Age, years (mean±SD) |
45.6±15.3 |
46.6±15.3 |
46.0±15.4 |
| Histology (%) | |||
| Papillary |
89.0 |
90.4 |
88.7 |
| Follicular |
6.8 |
7.6 |
7.8 |
| Hürthle cell |
4.2 |
2.0 |
3.5 |
| Race/ethnicity (%) | |||
| Caucasian |
83.6 |
74.8b |
83.2 |
| Asian |
5.1 |
7.6 |
5.4 |
| Hispanic |
4.9 |
11.0 |
6.2 |
| Black |
4.4 |
5.3 |
4.4 |
| Other |
2.0 |
1.5 |
0.8 |
| History of prior radiation exposure (%) |
3.6 |
4.9c |
4.3d |
| NTCTCS Stage (%) | |||
| I |
44.1 |
45.7 |
42.7 |
| II |
27.8 |
24.4 |
28.2 |
| III |
24.0 |
25.2 |
25.3 |
| IV |
4.1 |
4.7 |
3.8 |
| Outcomes (n) | |||
| Disease present at entry |
385 |
82 |
211 |
| Dated recurrence |
298 |
37 |
169 |
| Death |
178 |
38 |
84 |
| Disease-related death | 58 | 13 | 30 |
Comparisons were made between those with TSH/TgAb values available, and those with missing data. The statistical differences were found to be significant (ap=0.01, bp=0.01) or borderline significant (cp=0.053) compared to patients with missing TSH values, and significant (dp=0.03) compared to patients with missing TgAb status.
TSH, thyrotropin; TgAb, antithyroglobulin antibodies.